Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy

Distler, Marius; Rückert, Felix; Dittert, Dag-Daniel; Stroszczynski, Christian; Dobrowolski, F.; Kersting, Stephan; Grützmann, Robert

doi:10.1186/1477-7819-7-22

Cited by 40 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considered the standard of care for pancreatic adenocarcinoma, palliative treatment with gemcitabine, either alone or as combination therapy, has shown benefit in some reports but disappointing in others17, 22, 24, 25. Some activity has been noted with 5-fluorouracil2, 19 and paclitaxel (present study23). Because of the small number of cases, it is difficult to draw definitive conclusions regarding the best approach to systemic therapy.…”

Section: Discussionmentioning

confidence: 73%

An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development

Armstrong¹,

Hoff²,

Barber³

et al. 2011

J. Cancer

View full text Add to dashboard Cite

Acinar cell carcinoma of the pancreas is an uncommon malignancy, accounting for less than 1% of all pancreatic neoplasms. Because of its rarity, only a few retrospective studies are available to help guide management. We report the case of a patient with metastatic ACC who achieved prolonged survival as a result of personalized treatment designed in part on the basis of molecular and in-vitro data collected on analysis of the tumor and a cell line developed from the liver metastasis. To our knowledge, this represents the first human cell line of ACC. The molecular findings on this case and this patient's cell line may be of use in the management of future cases of this rare tumor and allow the identification of potential novel targets for the effective treatment of this disease.

show abstract

Section: Discussionmentioning

confidence: 73%

An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development

Armstrong¹,

Hoff²,

Barber³

et al. 2011

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Others that have been used are gemcitabine, cisplatin, doxorubicin, irinotecan, oxaliplatin, docetaxel, capecitabine, 5-FU/leucovorin, erlotinib, sunitinib and sirolimus. If the acinar cell carcinoma is unresectable, patient should be treated by 5-FU chemotherapy either with a neoadjuvant or palliative intention [17,18]. Treated acinar cell carcinomas may show histologic changes including fibrosis and accumulation of histiocytes.…”

Section: Treatmentmentioning

confidence: 99%

Acinar Cell Carcinoma of the Pancreas: A Literature Review and Update

Chaudhary

2014

Indian J Surg

View full text Add to dashboard Cite

Pancreatic acinar cell carcinoma is a rare tumour, accounting for only about 1 % of all pancreatic tumours. The long-term survival for patients with acinar cell carcinoma is significantly better than the long-term survival of patients with pancreatic adenocarcinoma. As no large series of patients with acinar cell carcinomas exist, our understanding of this disease comes mainly from small case series and case reports. Aggressive surgical resection with negative margins is associated with long-term survival in these more favourable pancreatic cancers. There are no clear treatment guidelines for patients in whom complete surgical resection with curative intent is not possible. Acinar cell carcinomas are chemoresponsive to agents that have activity against pancreatic adenocarcinomas and colorectal carcinomas because of the shared genetic alterations between these cancers. The role of neoadjuvant or adjuvant chemoradiotherapy remains unproven. The aim of this article is to present current knowledge on acinar cell carcinoma and comprehensive review of available literature.

show abstract

“…Therefore, effective chemotherapy is necessary to improve the clinical outcome. However, chemotherapy regimens have not been established due to the rarity of this disease [19,20]. A study carried out in the Memorial Sloan-Kettering Cancer Center of 18 ACC patients who received in-homogeneous chemotherapy regimens, containing Gemcitabine, 5-FU, Leucovorin, Mitomycin, Cisplatin, Cytarabine, Irinotecan, Caffeine and Doxorubicin, reported partial responses (PRs) and stable disease in some patients.…”

Section: Discussionmentioning

confidence: 99%

Acinar Cell Carcinoma of the Pancreas with Postoperative Lipase Hyper-Secretion Syndrome: Case Report and Review of the Literature

2017

ARC Journal of Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Curative resection of a primarily unresectable acinar cell carcinoma of the pancreas after chemotherapy

Abstract: Background: Acinar cell carcinoma (ACC) represents only 1-2% of pancreatic cancers and is a very rare malignancy. At the time of diagnosis only 50% of the tumors appear to be resectable. Reliable data for an effective adjuvant or neoadjuvant treatment are not available.

Cited by 40 publications

References 19 publications

An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development

An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development

Acinar Cell Carcinoma of the Pancreas: A Literature Review and Update

Acinar Cell Carcinoma of the Pancreas with Postoperative Lipase Hyper-Secretion Syndrome: Case Report and Review of the Literature

Contact Info

Product

Resources

About